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ABSTRACT
Although circulating DNA (ctDNA) could be an at-
tractive tool for early cancer detection, diagnosis,
prognosis, monitoring or prediction of response to
therapies, knowledge on its origin, form and rate of
release is poor and often contradictory. Here, we
describe an experimental system to systematically
examine these aspects. Nude mice were xeno-
grafted with human HT29 or SW620 colorectal
carcinoma (CRC) cells and ctDNA was analyzed by
Q–PCR with highly specific and sensitive primer sets
at different times post-graft. We could discriminate
ctDNA from normal (murine) cells and from mutated
and non-mutated tumor (human) cells by using
species-specific KRAS or PSAT1 primers and by as-
sessing the presence of the BRAF V600E mutation.
The concentration of human (mutated and non-
mutated) ctDNA increased significantly with tumor
growth. Conversely, and differently from previous
studies, low, constant level of mouse ctDNA was
observed, thus facilitating the study of mutated
and non-mutated tumor derived ctDNA. Finally,
analysis of ctDNA fragmentation confirmed the pre-
dominance of low-size fragments among tumor
ctDNA from mice with bigger tumors. Higher
ctDNA fragmentation was also observed in plasma
samples from three metastatic CRC patients in
comparison to healthy individuals. Our data
confirm the predominance of mononucleosome-
derived fragments in plasma from xenografted
animals and, as a consequence, of apoptosis as a
source of ctDNA, in particular for tumor-derived
ctDNA. Altogether, our results suggest that ctDNA
features vary during CRC tumor development and
our experimental system might be a useful tool to
follow such variations.
INTRODUCTION
Extracellular or cell-free nucleic acids (DNA and
RNA) have been detected in several body ﬂuids such as
blood, urine, stools, milk, bronchial lavages or ascites.
Circulating DNA (ctDNA) was ﬁrst found in plasma
samples by Mandel and Metais (1) and, only many years
later, Stroun and coworkers determined that ctDNA in
cancer patients’ plasma originated from tumor cells (2).
Technical advances in the detection and quantiﬁcation
of RNA and DNA have widened the possibilities of mo-
lecular diagnosis and monitoring of diseases (3).
Speciﬁcally, ctDNA was found to carry tumor-associated
genetic alterations and thus, for more than a decade, it has
been considered as a potential cancer diagnostic marker
for a non-invasive test (3,4).
Indeed, many cancer patients present increased plasma/
serum concentration of ctDNA in comparison to the
majority of the healthy subjects tested (reviewed by
Fleischhacker and Schmidt) (5), although inﬂammation,
trauma or exhaustive exercise can lead to higher plasma/
serum ctDNA concentrations also in controls. Moreover,
increased amount of plasma ctDNA is observed as the
tumor progresses (4–6) and high ctDNA level are found
in patients with advanced disease (7–10) or metastases (7)
and ctDNA levels higher than 1000ng/ml signiﬁcantly
correlate with shorter survival (11). However, despite the
numerous studies on this subject, there is no consensus
about the correlation between ctDNA concentration and
tumor stage, location and size (3,4,9).
In cancer patients, ctDNA originates from both normal
and tumor cells since ctDNA containing cancer-related
mutations appears to contribute only to a minor fraction
of the total ctDNA detected in plasma (12). The presence
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causes such as apoptosis, necrosis, direct release and
release from macrophages/scavengers following absorp-
tion of necrotic cells (12,13). Such events might arise in
tumor cells as well as in normal cells which surround the
tumor (12). The relative contribution of such mechanisms
in ctDNA release in blood circulation has not been
clariﬁed yet.
ctDNA half life has been estimated at about 16min
(10,12), suggesting that ctDNA is not ‘naked’ but rather
complexed with cellular or non-cellular components.
ctDNA physico-chemical characteristics are poorly docu-
mented but it might be associated with cell membrane
parts, speciﬁc or non-speciﬁc DNA-binding proteins
(14), apoptotic bodies (15) or multi-nucleosome complexes
(16,17). Discrepancies about ctDNA size in serum/plasma
exist in the literature certainly due to technical limitations.
ctDNA size was found to range from 500bp to >30kb
(18–20); however, recent studies described ctDNA frag-
ments smaller than 250bp (6,12,13). The size distribution
of ctDNA fragments within the same plasma/serum
sample has been poorly studied (20,21). Moreover,
analysis of ctDNA size as a diagnostic marker is contro-
versial and appears to be of limited value, especially for
early diagnosis. Combining this parameter with more
speciﬁc ones might eventually be beneﬁcial.
ctDNA level is high in the blood circulation of patients
with colorectal carcinoma (CRC). CRC is one of the most
frequent cancers in adults and it is due to the cumulative
eﬀects of inherited genetic susceptibilities and environ-
mental exposures (10,12,21,22). Accumulation of genetic
alterations in a multistep process characterizes the devel-
opment of sporadic CRC. Chromosomal instability,
microsatellite instability and CIMP (CpG island methyla-
tor phenotype) are the diﬀerent pathways that permit
the progressive accumulation of gene mutations
which will cause colon cancer. A CRC carcinogenesis
model involves the successive accumulation of APC
(Adenomatous Polyposis Coli), KRAS or BRAF and
TP53 mutations during tumor progression from
adenoma to advanced carcinoma (23). As a consequence,
knowing the mutation status of a patient may be import-
ant for CRC management, and therefore many studies
have focused on the analysis of DNA sequences from
tumor sections and more recently also from ctDNA (24).
Moreover, the demonstration that response to anti-
endothelial growth factor receptor (EGFR) therapies are
strongly limited or even abolished when the KRAS or
BRAF oncogenes are mutated (35–50% of metastatic
CRCs) (25,26), clearly boosts the development of a
more rapid, less costly and non-invasive approach for
determining the mutation status of metastatic CRC cells.
Analytical experimental tools, such as animal models,
could help optimizing a less costly, rapid and non-invasive
mutation detection test that makes use of ctDNA which is
accessible through a blood test. However, when consider-
ing abnormal ctDNA as a biomarker of malignancy,
crucial questions which remain unanswered, are hindering
its development. We thus wanted to investigate the form/
structure of ctDNA in animals xenografted with cancer
cells and healthy controls. Indeed, these ctDNA features
are poorly described while they might provide clues on
(i) the mechanisms of its release; (ii) their inﬂuence on
its extraction, analysis or pharmacokinetics; and (iii) the
progression of the disease. In addition, neither the cell
type (tumor or not) from which ctDNA originates nor
the fraction of ctDNA that carries cancer-related muta-
tions have been assessed so far. In order to use ctDNA as
a diagnostic tool we developed a mouse animal model and
molecular tools to systematically examine side by side
those critical aspects.
Athymic nude mice xenografted with human CRC cells
allowed us to unequivocally compare tumor- and non-
tumor-derived ctDNA amounts released during CRC ex-
pansion. Using very speciﬁc and sensitive Q–PCR
(Quantitative Polymerase Chain Reaction) systems we
could discriminate sequences of human and mouse
origin, quantify the proportion of mutated ctDNA
and evaluate ctDNA fragmentation. Quantiﬁcation of
ctDNA derived either from mouse or human cells was
carried out by targeting species-speciﬁc sequences in
KRAS and PSAT1. KRAS (3,5) Single nucleotide poly-
morphism (SNP) mutations are frequently associated
with CRC and PSAT1 is often over-expressed and
implicated in CRC progression and chemoresistance
(27). A reﬁned method for quantifying ctDNA fragments
that carry mutations was assayed in plasma of mice xeno-
grafted with HT29 cells and with primers that speciﬁcally
detect the BRAF V600E SNP mutation which charac-
terizes this CRC cell line. ctDNA fragmentation was
evaluated in order to estimate the contribution of apop-
tosis to ctDNA release by using an original double
integrated PCR system which targets two ACTB se-
quences of mouse or human origin. Finally, the clinical
relevance of the determination of ctDNA fragmentation
was preliminary assessed in plasma samples from a small
number of CRC patients and healthy controls.
MATERIALS AND METHODS
The presentation of the data in this report follows the very
recent MIQE (Minimum Information for Publication
of Quantitative Real-Time PCR Experiments) guide-
lines (28).
Cell lines and reagents
Human HCT116-s, SW620 and HT29 cells and mouse
MC38 CRC cells were maintained in RPMI +10% fetal
bovine serum. The HCT116-s cell line (29) is derived from
the CRC HCT116 which has the heterozygous KRAS
c.38G>A mutation. SW620 cells have the homozygous
KRAS G12V mutation (GGT to GTT), whereas HT29
cells exhibit the heterozygous BRAF V600E mutation
(30). The G12V mutation represents the most abundant
KRAS SNP in CRC (35–45% of CRC cases) (31), and
BRAF V600E (8–14% of CRC case) is highly predominant
relative to other BRAF SNPs in CRC (85–95%) (30).
This mutation was previously named V599E before
newly available sequence data by the National Centre
for Biotechnology Information (NCBI) gene bank. In
addition to be highly representative of frequent mutations
6160 Nucleic Acids Research, 2010,Vol.38, No. 18in CRC, both cell lines tend to form large solid tumors
following s.c. injection.
Oligonucleotides
The sequences of the oligonucleotide primers used in this
work—designed and selected here—are summarized in
Table 1. Primers were designed and selected according
to the following requirements: (i) Tm ranging from 57
to 64 C; (ii)GC% ranging from 45 to 65%; (iii) size
ranging from 18 to 26nt; (iv) amplicon size ranging
from 190 to 230bp, except for the ACTB primers used
for the integrity index; (v) self-assembling or internal an-
nealing energy <–5kcal. They were designed using the
Primer 3 software. We performed local-alignment
analyses with the BLAST program. The genome annota-
tion ﬁle for known and predicted genes (seq_gene.md) was
obtained from NCBI. Sequences were checked for self- or
inter-molecular annealing with nucleic-acid-folding
software (mfold and oligoAnalyzer 1.2). Oligonucleotides
were synthesized and puriﬁed on HPLC by MWG
(Ebersberg, Germany). Quality control of the oligonucleo-
tides was performed by MALDI TOF.
Xenograft model
Female athymic nude mice (6–8 weeks old) were pur-
chased from Harlan (Gannat, France) and maintained
in a speciﬁc pathogen-free facility in an accredited estab-
lishment (N  B-34-172-27; Institut de Recherche en
Cance ´ rologie de Montpellier-CRLC Val d’Aurelle-Paul
Lamarque, Montpellier, France). All experiments
complied with current national and institutional regula-
tions and ethical guidelines and were performed by an ac-
credited person (Dr B. ROBERT, N 34-156). Mice were
xenografted subcutaneously with 1 10
6 cancer cells.
Mice were euthanized with CO2 at diﬀerent time points
post-graft. Tumors were collected and weighed. Peripheral
blood was drawn into EDTA tubes and was immediately
(within 1h) used for plasma preparation.
Human blood samples
Blood samples from patients with untreated metastatic
CRC (mCRC) and from selected healthy individuals
(age<30 years) were collected in EDTA tubes (Conven-
tion EFS-PM: 21/PVNT/MTP/CNR14/2007-0046). The
overall process from blood collection to plasma prepar-
ation did not exceeded 3h and plasma was stored at
 80 C.
Plasma and serum preparation
Following collection in 5ml BD vacutainer KE35 tubes
(Belliver Industrial), mouse blood samples were
centrifuged at 2000rpm at 4 C in a Heraeus Multifuge
LR centrifuge with a CR 4j rotor for 10min.
Supernatants were collected in sterile 1.5ml Eppendorf
tubes and centrifuged at 14000rpm at 4 C for 10min.
Then supernatants were either immediately handled for
DNA extraction or stored at  80 C. No signiﬁcant diﬀer-
ence was found in Q–PCR assays when comparing freshly
isolated or stored plasma. Serum was prepared using the
same two-step centrifugation process, but blood was
drawn in tubes without EDTA which were then left at
room temperature for 1h. Mouse and human plasma
and sera were handled within 3h following sampling.
DNA extraction
ctDNA and genomic DNA from the diﬀerent cell lines
were extracted following the same procedure. DNA was
puriﬁed from 200ml plasma with the QIAmp DNA mini
Blood kit (Qiagen, CA) according to the ‘Blood and body
ﬂuid protocol’ with an elution volume of 60ml. Samples
Table 1. Characteristics of the selected primers and of the amplicons obtained
Species Gene Location Primer name Orientation Sequence 50–30 Tm ( C) Amplicon
size (bp)
Amplicon
Tm( C)
Human PSAT1 intron 7 PSAT1 Hf 5 Sense GGGTAGGTCCCGTCTACTCC 63.5 219 80,5
PSAT1 Hr 5 Antisense CCAAAGCCAATTCCATTCAC 55.2
Mouse PSAT1 50 ﬂanking
sequence
PSAT1 Mf 4 Sense GGCTTCGTTCTTGTGCAACT 57.3 230 84,5
PSAT1 Mr 4 Antisense ATGAGCTGGTGGAACCTGAC 59.4
Human KRAS intron 2 KRAS Hf 2 Sense AATCCGTGTGGGTCAGAGAG 59.4 189 76,5
KRAS Hr 2 Antisense GAAACAATAGCCACCCTCCTT 57.9
Mouse KRAS intron 2 KRAS Mf 3 Sense GGCCAGGAGTGCATTAAGAC 59.4 214 81,5
KRAS Mr 3 Antisense GCACGTCAGATAGTCTCCAAA 57.9
Human ACTB intron 8 HuACTB4353f Sense GGGACTATTTGGGGGTGTCT 60.05 133 83,7
HuACTB4510f Sense ACCTATGGGATCGTGGCTGT 61.70 290 77,8
HuACTB4643r Antisense CCCCTACCCCAACTTGACTT 60.22
Mouse ACTB intron 4 MoACTB2156f Sense CTTCTGCCGTTCTCCCATAG 59.83 120 82,5
MoACTB2374f Sense GATGCACAGTAGGTCTAAGTGGAG 59.37 338 83,5
MoACTB2494r Antisense CACTCAGGGCAGGTGAAACT 60.30
Human BRAF Exon 15 BRAF human f Sense AGGTGATTTTGGTCTAGCTACAGT 57.65 149 81.2
BRAF V600E f Sense GATTTTGGTCTAGCTACAGA 49.65 145 80.8
BRAF human r Antisense TAGTAACTCAGCAGCATCTCAGG 58.83
Human Kras Intron 2 Kras 145 Hf Sense TGGGCTGTGACATTGCTG 60.42 145 82.4
Kras 300 Hf Sense GGTCCTTTTCCGTGTGTAGG 59.45 300 83.6
Kras 145-300r Antisense TGACCAAGCAAAACAGACCA 60.28
Nucleic Acids Research, 2010,Vol.38, No. 18 6161were kept at 4 C during plasma preparation. DNA
samples were frozen at  20 C until use. No signiﬁcant
diﬀerence was found in Q–PCR assay when comparing
freshly extracted or stored DNA. Human HCT116-s and
mouse MC38 cells were grown to exponential phase and
5 10
6 cells were rinsed and DNA extracted. DNA con-
centration was determined with a Nanodrop spectropho-
tometer and 50ml aliquots of 1–2mg/ml DNA were kept at
 20 C until use.
CtDNA quantiﬁcation by Q–PCR
DNA was quantiﬁed by Q–PCR assay. Real-time PCR
ampliﬁcations were carried out in a reaction volume of
25ml on a My iCycler IQ 5IQ or a Chromo4 instrument
using the IQ5 Optical system software 2.0 and the MJ
Opticon Monitor 3 software (Bio-Rad). Each PCR
reaction mixture consisted of 12.5ml mix PCR (Bio-Rad
Super mix SYBR Green=Taq polymerase, MgCl2); 2.5ml
of each ampliﬁcation primer (100pmol/ml); 2.5ml
PCR-analyzed water and 5ml DNA extract. Thermal
cycling started by a ﬁrst denaturation step of 3min at
95 C, followed by 40 cycles of 95 C for 10s and 60 C
for 30s. Melting curves were obtained from 55 to 90 C
with reading every 0.2 C. As calibrators for quantiﬁca-
tion, serial dilutions of genomic DNA from HCT116-s
and MC38 cells were used. Sample concentrations were
extrapolated from the standard curve by the IQ
5 Optical system software 2.0 or MJ Opticon Monitor
3 software. The copy number was calculated assuming
a DNA content of 6.6pg per cell and a length of
6.6 10
9bp. We expressed the limit of detection as the
concentration that can be detected with reasonable cer-
tainty (95% probability) as recommended in the MIQE
guidelines (28). The ﬁnal mean ctDNA calculation of a
sample was made by excluding ‘non-ampliﬁcation’ repli-
cates from the sample mean value. Each sample was
analyzed in duplicate and each assay repeated at least
once. Details are provided in Supplementary Data (S4).
Q–PCR targeted sequences
In this study we examined the variation of the amount of
various types of ctDNA in xenografted mice by Q–PCR
analysis of regions from four diﬀerent mouse or human
genes: KRAS, BRAF, PSAT1 and ACTB. Comparison of
human versus mouse ctDNA concentrations was carried
out by targeting two diﬀerent ‘one copy/genome’ genes
(KRAS and PSAT1) in order to limit potential unexpected
variations due to factors such as gene location or presence
of pseudogenes. KRAS was targeted in intron 7 and
PSAT1 in the 50 ﬂanking region. PSAT1 codes for a
phosphoserine aminotransferase which was shown to be
over-expressed in colon tumors (27). PSAT1 has also be
implicated in colon cancer progression and chemo-
resistance (27). Quantiﬁcation of mutated fragments was
ascertained by detecting ctDNA containing the BRAF
V600E mutation which is frequently associated with
CRC. Evaluation of ctDNA fragmentation was assayed
in an original double integrated PCR system that targets
ACTB sequences of mouse or human origin. ACTB is a
reference gene conventionally used for normalizing
various biological assays, in particular PCR; human
ACTB has been recently targeted in a single integrated
PCR system for estimating ctDNA integrity (32). To
improve direct comparison of the ampliﬁcation values,
the reverse primer for each ampliﬁcation system (human
or mouse) was the same for the short (133 and 120bp,
respectively) and the long fragment (290 and 338bp).
The non-species-speciﬁcity level of the oligonucleotide
primer sets was determined as the percentage of DNA
concentration obtained when analyzing a known concen-
tration of DNA from the other species.
Detection of ctDNA that carries the BRAF V600E
mutation
Detection of the BRAF V600E mutation was based on
the reﬁnement of the allele speciﬁc Q–PCR procedure
(AS PCR, which uses a primer system containing a sense
primer that includes the mutated nucleotide in the 30
position, 28) which combines the addition of an oligo-
nucleotide blocker (ASB–PCR, 33). Optimization of the
conditions of the assay and of oligonucleotide design was
based on the work by Morlan et al. (33). The selected
blocker was an oligodeoxynucleotide complementary to
the wild-type sequence but phosphorylated at the 30-end:
50-GCTACAGTGAAATCTCGATGG—PHO. Ampliﬁ-
cation and analysis by ASB Q–PCR was carried out as
described earlier using SYBR green as detection system.
The non-speciﬁcity level of the V600E ASB Q–PCR
system was determined as the percentage of DNA concen-
tration obtained when analyzing a known concentration
of wild-type genomic DNA (i.e. 0.5ng/ml, equivalent to
15ng/ml plasma DNA). Data analysis showed that the
V600E ASB–PCR system exhibited 0.2% non-speciﬁcity
(Supplementary Data S3).
Estimation of the ctDNA fragmentation
We used two primer sets targeting ACTB in human or
mouse ctDNA. Primers were designed as such that the
annealing sites of the shorter DNA fragments were
within the larger fragment. The degree of fragmentation
of ctDNA was assessed by calculating an index we termed
DNA Integrity Index (DII). DII was calculated as the
ratio of larger/shorter fragment concentrations. DII
is therefore theoretically 1 if the template DNA is not
truncated and <1 if it is truncated into fragments
smaller than the large fragment. Primer sets for the
short fragments were designed as such that the size of
the amplicon was smaller than the size of the DNA
involved in one nucleosome (133 and 120bp for human
and mouse ctDNA quantiﬁcation, respectively). The size
of the larger amplicon was of 290 and 338bp (correspond-
ing to a DNA length lower than that involved in two
successive nucleosomes) for human and mouse ctDNA
quantiﬁcation (Figure 8). DII determination in human
plasma with the ACTB Q–PCR system was conﬁrmed
by using another two primer sets that target a KRAS
intron region and generate 145 and 300bp amplicons
(Table 1). Values obtained were normalized with an
internal control by determining the DII of human
6162 Nucleic Acids Research, 2010,Vol.38, No. 18placenta DNA (Sigma Aldrich, Ref D 3035) that has a
theoretical DII of 1.
Statistical analysis
Data were expressed as mean ± SD. Statistical analyses
were performed using the Student’s t-test for comparison
of means. A probability of <0.05 was considered to be stat-
istically signiﬁcant; *P 0.05, **P 0.01, ***P 0.001.
RESULTS
Quality control of the selected Q–PCR primer sets
We ﬁrst validated the diﬀerent sets of primers (Table 1)
to be used for ctDNA characterization by Q–PCR using
genomic DNA from human (HCT116-s) and mouse
(MC38) CRC cell lines and ctDNA from controls and
CRC patients as well as from control and xenografted
nude mice.
DNA quantiﬁcation. The quantiﬁcation of a given genomic
DNA sample by Q–PCR under our experimental con-
ditions showed some variation according to the primer
set employed. This discrepancy was much higher when
comparing the ACTB primer sets used to assess DNA
fragmentation. Hence, we applied a correlation factor
when determining the DNA amount with each primer
set in order to precisely compare the quantiﬁcation of
speciﬁc DNA sequences in ctDNA from mouse blood.
This correlation factor was calculated from the equation
for Cqi ny versus the concentration in the x-axis, respect-
ively, and the R
2 for each PCR primer set which are pre-
sented in Supplementary Data S1.
Sensitivity. Sensitivity of our quantiﬁcation system was
assayed using serially diluted genomic DNA from
human HCT116-s and mouse MC38 cell genomic DNA
and the primer sets KRAS H2 (human) (Figure 1) and
KRAS M3 (mouse). Both assays produced log-linear
curves (y= 3.217x+23.698 with a R
2=0.997;
y= 3.424x+24.065 with a R
2=0.998, respectively).
The number of PCR cycles required to detect one copy
of the target gene, as theoretically indicated by the y inter-
cepts, was 34.5 for KRAS H2 and 35.3 for KRAS M3.
Figure 1 presents the values obtained from the standard
curve of seven diﬀerent Q–PCR experiments and illus-
trates the sensitivity of our assay when using the same
HCT116-s genomic DNA sample and the KRAS H2
primer set. The linear dynamic range covered at least
four orders of magnitude. Accuracy of quantiﬁcation
was evaluated using the limit of detection of the assay,
which was seven DNA copies (10pg/ml of DNA), as
determined when 95% of the positive samples are
detected. We optimized sample acquisition, handling and
preparation to hinder experimental variability. No signiﬁ-
cant discrepancy concerning sensitivity was observed
when analyzing DNA from blood samples or from
cultured cells. A reproducibility test carried out on 12 ex-
periments that used a ctDNA pool from four CRC
patients’ sera and the PSAT1 M4 primer set showed a
coeﬃcient of variation of 19% (data not shown).
Species-speciﬁcity. KRAS H2 and PSAT1 H5 (human)
and KRAS M3 and PSAT1 M4 (mouse) were chosen
among 15 other Q–PCR primer sets because they could
accurately, reproducibly and sensitively quantify human
and mouse DNA, respectively. Speciﬁcity of these
Q–PCR primer sets was evaluated using plasma ctDNA
from control BALB/C mice (Figure 2A) and healthy
human individuals (Figure 2B). ctDNA level averaged
1ng/ml in healthy human plasma when using the KRAS
H2 and PSAT1 H5 primer sets, while no detectable
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Figure 1. Sensitivity of the Q–PCR assay determined by plotting Cq and ctDNA concentrations on the y and x axis, respectively. Q–PCR analysis
was performed using the KRAS H2 primer set with HCT116-s cell genomic DNA. Data obtained from seven diﬀerent experiments are combined;
each value obtained during these seven experiments carried out in separate runs is represented. The mathematical trend curve was a line of the
equation y=–1.3538 ln(x)+25353 (R
2=0.8973). Each individual standard curve from the seven experiments exhibited a R
2>0.99. ctDNA con-
centration was expressed as ng/ml plasma and copies/assay. A factor of 6.6pg of DNA per diploid cell is used for copy number conversion. The
absolute equivalent amount of DNA in each sample was determined by a standard curve with serial DNA dilutions in 5ml (50ng–0.05pg) in 25ml
total reaction volume.
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(Figure 2B). Similarly, no detectable or very low amount
(mean 0.1ng/ml, <0.8%) was observed with KRAS H2
and PSAT1 H5, respectively, in control mouse plasma,
contrary to the 13–23ng/ml range found with KRAS M3
and PSAT1 M4 (Figure 2A). This high Q–PCR ampliﬁ-
cation speciﬁcity was further conﬁrmed as no ampliﬁca-
tion could be detected using PSAT1 H5 and KRAS H2
with MC38 genomic DNA or using PSAT1 M4 and
KRAS M3 with HCT116-s DNA extracts (data not
shown).
DNA integrity. ctDNA fragmentation was evaluated
using an original double integrated PCR system which
targets two ACTB gene sequences of mouse or human
origin (Figure 8). Twelve diﬀerent ACTB primer sets
were designed and tested according to the plan presented
in Figure 8.
The species-speciﬁcity of the primer sets was assessed by
determining the concentration values obtained from the
ampliﬁcation of genomic DNA extracts from mouse
MC38 and HCT116-s colon cancer cells (Supplementary
Data S2). The chosen human ACTB primer sets appeared
to be highly speciﬁc (97.77 and 97.83%). Conversely,
despite our eﬀorts, we could not design similarly highly
speciﬁc mouse ACTB primer sets (only 94.44 and 96.23%)
and the concentration obtained with both mouse primer
sets appeared over-estimated by about 2-fold. Thus, a cor-
relation factor was applied.
Detection of mutated ctDNA fragments. Quantiﬁcation of
the BRAF V600E mutation was performed by Allele
Speciﬁc Q–PCR with blocker (ASB–PCR) using an
original oligonucleotide blocker and an original primer
set speciﬁc for the mutation (Table 1) which demonstrated
high speciﬁcity (99.8%). No mutation was detected in
DNA extracts of mouse MC38 colon cancer cells
(Supplementary Data S3A), or in the blood of control
mice or mice xenografted with SW620 cells, which do
not carry this mutation.
Plasma is a better source of tumor-derived ctDNA
than serum
After having validated our Q–PCR system, we then com-
pared plasma and serum as a possible source of ctDNA.
For this we used nude mice xenografted with SW620 CRC
cells from which blood was drawn on various days
post-xenograft. Plasma ctDNA level (ranging from 0.5
to 12.2ng/ml) did not vary greatly when using the
mouse-speciﬁc KRAS or PSAT1 primer sets and ctDNA
concentration was not related to the tumor weight
(Figure 3A and B). Except for mouse 1 (Mo1), mouse-
derived ctDNA level was higher in serum than in
plasma. Conversely, the concentration of ctDNA of
human origin highly varied (from 0.05 to 408ng/ml and
from 2 to 88ng/ml) when using the KRAS H2 or PSAT1
H5 primer sets (Figure 3C and D, and data not shown).
Moreover, the median values of human ctDNA was about
2- to 3.5-fold lower in serum than in plasma using either
the KRAS or PSAT1 primer sets (3.7 and 4.5 versus 1.0
and 2.2 in plasma and serum, respectively). Finally, mouse
4 (Mo4) exhibited the highest tumor weight (2880mg) and
showed the highest ctDNA level. Thus, the tumor-derived
ctDNA concentration was much higher in plasma than in
serum (32-fold with the KRAS H5 and 5.3-fold with the
PSAT1 primers), whereas mouse-derived ctDNA was
higher in serum (2.5- and 2-fold, respectively). In
addition, no human derived ctDNA was detected in the
serum of the mouse with the smallest tumor (mouse 1,
Mo1). These results also suggest that the concentration
of human-derived ctDNA in plasma, and to a lesser
extent in serum, is higher in mice with higher tumor
weight. Our results indicate that plasma is a better
blood fraction for discriminating tumor ctDNA by Q–
PCR analysis. We accordingly decided to use plasma
instead of serum for all the experiments described
hereafter.
In xenografted mice the concentration of tumor-derived
ctDNA is positively correlated with tumor weight
The previous results indicate that the concentration
of tumor-derived (human) ctDNA can exhibit huge
inter-sample diﬀerences. Since Q–PCR quantiﬁcation did
not show signiﬁcant variations when the same genomic
DNA samples from mouse or human origin were
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Figure 2. Evaluation of the speciﬁcity of the Q–PCR systems targeting
KRAS and PSAT1. Human KRAS H2, mouse KRAS M3, human
PSAT1 H5 and mouse PSAT1 M4 primer sets were tested using
plasma ctDNA extracts either from BALB/C mice (A) or from
healthy human individuals (B). Results of ampliﬁcations with these
PCR systems were expressed as plasma ctDNA concentration (ng/
ml). Dark and light histograms represent the values of ctDNA concen-
tration assessed in duplicates.
6164 Nucleic Acids Research, 2010,Vol.38, No. 18ampliﬁed with either the KRAS M3 or the PSAT1 M4
primer set or the KRAS H2 or PSAT1 H5 primer set,
respectively (data not shown), we wanted to determine
whether this diﬀerence was due to the type and the size
of the tumor. For this, we quantiﬁed human and mouse
ctDNA from plasma of mice xenografted with SW620 or
HT29 CRC cells (obtained at various days post-graft)
using the human and mouse KRAS and PSAT1 primer
sets. Similar to the results obtained in mice xenografted
with SW620 cells (Figure 3), in mice xenografted with
HT29 cells (Mo6–Mo10) we observed a marked diﬀerence
in the concentration of mouse and human (tumor-derived)
ctDNA, not only when targeting the human and murine
KRAS gene (Figure 4B), but also when using the PSAT1
primer sets (Figure 4A). Speciﬁcally, comparable ctDNA
amounts (around 1ng/ml) were found in all HT29 xeno-
grafted mice when mouse KRAS and PSAT1 were
ampliﬁed (Figure 4D). In contrast, human ctDNA con-
centrations were highly variable and were noticeably
higher in mice with bigger tumors (Figure 4A, B and C).
Plasma ctDNA concentration determined using the KRAS
H2 primer set was higher than the one obtained from
PSAT1 H5, but in both cases the progressive increase of
tumor-derived ctDNA relative to the tumor weight was
clearly observed (Figure 4C). Indeed, the mouse with the
highest tumor weight (>1000mg, Mo10) showed the
highest concentration diﬀerence between human-derived
and mouse-derived ctDNA both with the KRAS
H2 primer set (11.5-fold higher) and the PSAT1 H5
set (4-fold higher). Finally, no human-derived ctDNA
was detected in the mouse with the smallest tumor
(Mo6, 130mg) when targeting human KRAS and
PSAT1 (Figure 4C), while mouse-derived ctDNA was
still detectable (Figure 4D).
Similar results were obtained in mice xenografted with
SW620 cells when mouse KRAS or PSAT1 were targeted
( 0.5ng/ml) (Figure 5A and B, respectively). No detect-
able human-derived ctDNA was observed in the
non-xenografted control Mo11 and in Mo12 in which
the graft was unsuccessful (following injection, SW620
cells did not proliferate and the tumor was undetectable
even at autopsy) (Figure 5C and D). Human-derived
ctDNA level was much higher (25- and 7-fold) in Mo14
(with the heaviest tumor) than in Mo13. ctDNA levels
appeared higher when targeting KRAS sequences than
when targeting PSAT1 in both HT29 or SW620 xeno-
grafts. Moreover, the tumor-related ctDNA level was
slightly lower relative to the tumor weight in SW620 xeno-
grafts than in HT29 xenografts (Figure 4). The observa-
tions about the increase of tumor ctDNA amount with
2880 710 610 210 2880 710 610 210
Tumorweight
(mg)
A
D
B
C
Figure 3. Comparison of ctDNA amount from serum (light bars) and plasma (dark bars) preparations. ctDNA concentration in plasma and serum
from SW620 xenografts was determined using the mouse KRAS M3 (A), mouse PSAT1 M4 (B), human KRAS H2 (C) and human PSAT1 H5 (D)
primer sets. ctDNA concentration for each mouse (Mo1, Mo2, Mo3 and Mo4) and the corresponding tumor weight (210, 610, 710 and 2880mg,
respectively) are shown. Values were calculated from duplicate experiments carried out twice.
Nucleic Acids Research, 2010,Vol.38, No. 18 6165tumor weight and about the stability of the non-tumor
ctDNA concentration irrespective of the tumor weight
were conﬁrmed when using the human ACTB primer
sets (Table 2).
Mutated ctDNA is easily detectable
In order to assess whether tumor-derived ctDNA could be
used to evaluate the mutation status of a tumor, we used
ctDNA samples from mice xenografted with HT29 cells
and speciﬁc human BRAF primer sets (Table 1) to detect
the V600E mutation of BRAF which characterizes HT29
CRC cells (Figure 6). In a ﬁrst experiment we used the
same group of animals previously used to study tumor
versus non-tumor ctDNA concentrations (Mo5–Mo10,
Figure 4). Huge variability was observed in the concentra-
tion of ctDNA when mutated and non-mutated human
BRAF sequences were targeted (Figure 6A). Conversely,
comparable amounts were found in control and xeno-
grafted mice when targeting mouse-derived ctDNA with
the mouse-speciﬁc KRAS primers. The BRAF V600E
mutation was detected in every HT29 xenografted
mouse, while four out of ﬁve ctDNA samples were positive
when using the KRAS H2 primer set. These results
were conﬁrmed in a second group of mice (Mo15–Mo22,
Figure 6B). The V600E PCR system is highly speciﬁc as
determined using mice xenografted with SW620 cells
which do not carry this mutation (S3). As observed
earlier (Figure 4), mouse-derived ctDNA level in HT29
xenografts remained rather constant irrespective of the
tumor weight (Figure 6B). To note, the concentration of
mutated ctDNA seemed in general lower than that of total
tumor ctDNA, particularly it was about half the total
amount in mice with high weight tumors (Mo10 and
Mo22). This can be explained by the monoallelic nature
of the V600E mutation in HT29 cells (30,34). Human
wild-type and mutated BRAF sequences could not be
detected in three diﬀerent control mice (Mo15–17).
Similar observations could be made when examining the
concentration of ctDNA fragments harboring the KRAS
G12V mutation in animals xenografted with SW620 CRC
cells, except that human wild-type and mutated ctDNA
exhibited comparable amounts in every mouse tested [ac-
cording to the homozygous characteristic of that mutation
in this cell line; (31,34)] (data not shown). Of course, the
BRAF V600E mutation was not detected in this animal
group and the KRAS G12V mutation was not detected in
HT29 xenografts, conﬁrming the speciﬁcity of the primer
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Figure 4. ctDNA concentration relative to tumor weight in plasma of HT29 xenografts. ctDNA concentrations determined by Q–PCR analysis
targeting human or mouse PSAT1 (A), human or mouse KRAS (B), human PSAT1 or KRAS (C) and mouse PSAT1 or KRAS (D) sequences were
plotted in linear regression curves. ctDNA values obtained with mouse PSAT1 M4 (open square), human PSAT1 H5 (closed square), mouse KRAS
M3 (open circle) and human KRAS H2 (closed circle) primer sets were expressed versus HT29 xenograft tumor weight. Control mouse (Mo5)
corresponds to a non-xenografted athymic nude mouse (tumor weight=0). Mo6–Mo10 bore tumors weighing 130, 280, 380, 400 and 1090mg.
Values were calculated from duplicate experiments carried out twice.
6166 Nucleic Acids Research, 2010,Vol.38, No. 18sets (data not shown). The ASB–PCR method (33) and the
molecular tools used to detect these mutations (SYBR
green and original primers) proved to be highly sensitive
and speciﬁc (99.8% for the BRAF V600E) apparently as
much as the Taqman Q–PCR assay for KRAS mutations
described by Morlan et al. (31).
Only the tumor-derived ctDNA level varies according
to the tumor burden
So far, we quantiﬁed the ctDNA concentration in the
plasma of each mouse and then individually compared
them relative to tumor growth or origin and targeted
sequence. Theoretically the same ctDNA concentration
should be obtained when targeting wild-type sequences
within a species owing to the equivalency of the PCR
primer system yield. In order to estimate in another
way the relationship between tumor size and the ctDNA
concentration determined by targeting mouse, human
wild-type or mutated sequences, we separated—irrespect-
ive of the targeted gene—all our data in three categories
based on tumor mass: high weight tumors (>500mg), low
weight tumors (100–500mg) and control, non-xenografted
nude mice (Figure 7). Due to the variation of ctDNA
amounts previously observed (Figure 4) when targeting
human PSAT1 and KRAS sequences, we calculated the
mean values for all the ctDNA concentrations obtained
using the KRAS and PSAT1 primers sets which ﬁt within
one of the three categories. Mouse-derived ctDNA level
was comparable in all groups (Figure 7) and human-
derived ctDNA was never detected in controls. In the
group of xenografted mice with low weight tumors,
almost equivalent levels of mouse and human ctDNA
were found in plasma ( 2.25 and 2.68ng/ml in HT29
xenografts). In mice with high weight tumors, both
human wild-type and mutated ctDNA levels were statis-
tically higher than in the low weight tumor group
(P>0.001 and P<0.05, respectively). In the high weight
tumor group, the mean concentration of human mutated
ctDNA was nearly 2-fold lower than that of wild-type
ctDNA, but the diﬀerence was not statistically signiﬁcant.
ctDNA fragmentation increases with ctDNA level
In order to assess ctDNA fragmentation in our animal
model, we followed the procedure recently described by
Ellinger et al. (32,35) who calculated an integrity index
using two primer sets that target the same ACTB
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Figure 5. Determination of ctDNA concentration in plasma of SW620 xenografts by Q–PCR analysis. Plasma ctDNA amounts were measured in a
control non-xenografted mouse (Mo11), in an unsuccessfully xenografted mouse (Mo12), and in mice with tumor of 640mg (Mo13) and 2470mg
(Mo14). Experiments were carried out in duplicate and conﬁrmed twice. Mouse KRAS (A), mouse PSAT1 (B), human KRAS (C) and human PSAT1
(D) primers correspond to KRAS M3, PSAT1 M4, KRAS H2 and PSAT1 H5. Data shown here are from a representative experiment performed in
a single run.
Nucleic Acids Research, 2010,Vol.38, No. 18 6167sequence. However, we could not use their primers as they
were not human-speciﬁc and strong non-speciﬁcity was
observed when they were used to analyze mouse-derived
ctDNA. Thus, we designed two speciﬁc primer sets for
human ACTB and two new ones for mouse ACTB in
order to compare fragmentation in human- and
mouse-derived ctDNA (Table 1 and Figure 8). A short
(133bp) and a long (290bp) DNA fragment from
human ACTB, and a short (120bp) and a long (338bp)
DNA fragment from mouse ACTB were ampliﬁed by Q–
PCR from the previously used plasma ctDNA samples
(Mo6–Mo12) to determine the DII (i.e. long/short
fragment ratio) within the same DNA sequence. Results
are summarized in Table 2. No ctDNA was detected when
the human ACTB primers were used to amplify the
plasma sample of the control mouse (Mo5) (Table 2,
panel A). It has to be noted that the ctDNA concentration
range obtained when targeting mouse ACTB was 5- to
10-fold higher than when targeting mouse KRAS or
PSAT1, while not being inﬂuenced by the tumor weight
as in the previous experiments (Table 2 and Figure 4). In
addition to diﬀerences in PCR eﬃciency, the presence of
multiple detectable ACTB pseudogenes should account
for this discrepancy (36). DII of human ctDNA ranged
Figure 6. Discrimination of mouse, human wild-type and mutated ctDNA amounts in xenografted mice. Two representative experiments (A and B)
are presented. Histograms describe the quantiﬁcation of wild-type mouse (black bar) and human wild-type (hatched bar) and mutated V600E ctDNA
(light bar). V600E BRAF mutated ctDNA amount was determined by ASB–PCR in Mo5–10, which had been xenografted with HT29 cells, and
compared to mouse (KRAS M3 primer set) and human (wild-type BRAF primer set) derived ctDNA (A). In the second experiment, plasma samples
of another ﬁve HT29 xenografted mice (Mo18–Mo22) and three non-xenografted control mice (Mo15–17) were used to quantify ctDNA using the
PSAT1 M4, wild-type BRAF and V600E BRAF primer sets (B). Experiments were carried out in duplicate in a single run and conﬁrmed twice. The
total concentration of human ctDNA can be obtained by adding together the amount of mutated and non-mutated ctDNA as the V600E mutation is
heterozygous in HT29 cells. ND, not detected.
6168 Nucleic Acids Research, 2010,Vol.38, No. 18from 0.06 to 0.22 and was 2.7- to 6.9-fold lower than that
of mouse ctDNA (0.17–1.19) (Table 2). Non-tumor DII of
control mice and of the mouse with very low tumor weight
(Mo6) were >1 in contrast to those of mice bearing high
and medium weight HT29 tumors (0.05–0.06) (Table 2,
panel A).
These observations were conﬁrmed by data from a
second experiment (Table 2, panel B). Human-derived
ctDNA could not be detected in the three control
healthy athymic nude mice (Mo23–25) while mouse
ctDNA DII averaged 0.71. The non-tumor/tumor DII
ratio in xenografted mice seemed to augment with
the increase of the tumor mass in both experiments
(2.67–6.93 and 0.86–2.67). Interestingly about a 2-fold
increase of this ratio was observed when comparing
HT29 xenografts bearing the two heaviest tumors in the
ﬁrst (0.4 and 1.09g) and in the second experiment (0.31
and 1.02g). To note, the non-tumor/tumor DII ratio was
about 2-fold higher in the ﬁrst experiment than in the
second one possibly due to lower non-tumor DII values
in the second experiment.
Clinical relevance of the DII values determined in the
animal model
To assess the clinical relevance of the data we obtained
in xenografted mice, we calculated the DII of ctDNAs
extracted from plasma samples of healthy and mCRC
subjects using the previously employed human ACTB
primer sets (amplicons of 133 and 290bp, Table 1) and
the wild-type KRAS PCR primer sets (amplicons of 145
and 300bp, Table 1). DII values obtained with the KRAS
primer sets for the plasma samples from the three healthy
individuals were 1.03, 1.76 and 2.75, whereas the DII of
the ctDNAs from the three mCRC patients were 0.31, 0.77
and 0.80 (Table 3). Speciﬁcally, the DII median value
(1.76) for plasma samples from healthy subjects was
2.3-fold higher than that of samples from mCRC
patients (0.77). DII values obtained with the ACTB
primer sets for the same three mCRC plasma samples
were 0.12, 0.4 and 0.72. Those values are <1 and
the plasma showing the signiﬁcant highest ctDNA concen-
tration (HCP003 sample) exhibited the lower DII, as
observed when using the KRAS Q–PCR system.
Whereas the DII median values of plasma samples from
healthy human individuals and control mice were similar,
the DII values determined in mCRC patients were slightly
higher than those found in xenografted mice (Table 2).
This discrepancy could be explained, at least partly, by
the higher tumor mass/weight ratio in xenografted mice.
Nevertheless, in both xenografted mice and mCRC
patients the DII values determined in plasma were lower
than those of healthy subjects/mice.
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Figure 7. ctDNA concentration and tumor burden. All the data obtained in this study (A) were combined and separated in three categories: mice
with high weight tumor (>500mg, n=5), low weight tumor (100–500mg, n=11) and non-xenografted nude mice (n=8). Number of mouse plasma
samples analyzed for each tumor mass category (B). In addition, we combined all KRAS and PSAT1 ctDNA concentrations obtained in this study
from mouse plasma samples of HT29 xenografts. Human derived (tumor mutated and non-mutated) ctDNA as well as mouse derived ctDNAs were
quantiﬁed in each category. Statistical evaluation of the signiﬁcance of the diﬀerences among groups (P-values, from the Student’s t-test) is presented
in Supplementary Data S5.
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We optimized a fast and sensitive Q–PCR assay to specif-
ically detect tumor (human) or non-tumor (mouse)
ctDNA in nude mice xenografted with CRC cells. The
use of our original primer sets for detecting KRAS,
PSAT1, BRAF or ACTB sequences showed a high
degree of discrimination for mouse/human sequences
owing to the absence of false positive signals. Targeting
KRAS, PSAT1 and BRAF in the same ctDNA plasma
sample provided similar results in terms of quantiﬁcation
and therefore validated and strengthened the assay. This is
crucial as discrepancies among genomic sequences might
occur such as, in our study, for ACTB which can probably
be explained by the presence of ACTB pseudogenes (36).
Table 2. ctDNA fragmentation relative to tumor progression in xenografts
          control    HT29 
mice   Mo5  Mo6  Mo7 Mo8 Mo9  Mo10 
[Human derived 
ctDNA] 
HuACTB 290  ND 
ND 2.96  0.23  0.5  1.18 
ng/ml  HuACTB 133  ND  2.7 13.3  4.65 4.81 19.12 
Tumor DII     0.22  0.05  0.1  0.06 
[Mouse derived 
ctDNA]  
MoACTB 338 
5.05 27.45  14.41 3.49  30.24  9.68 
ng/ml  MoACTB 120  3.19 22.73 24.2 20.89 99.21 22.55 
Non-tumor DII  1.59  1.19  0.59  0.17  0.31  0.43 
non-tumor DII /  
tumor DII 
      2.67  3.45  3.1  6.93 
Tumor weight (mg)  0 130  280  380 400  1,090 
  Control                HT29  
mice Mo23  Mo24  Mo25  Mo19  Mo20  Mo21 Mo22 
[Human derived 
ctDNA] 
HuACTB 290 
ND ND  ND  0.1  0.1  0.09 0.78 
ng/ml  HuACTB 133  0.19 ND  ND  0.23  0.34  0.85 12.32 
Tumor DII           0.43  0 .29  0.11  0.06 
[Mouse derived 
ctDNA]  
MoACTB 338 
8.99  5.63  14.85  4.05 1.46 1.79 4.26 
ng/ml  MoACTB 120  8.36 10.55 29.21  10.97  9.47  13.34 26.05 
Non-tumor DII  1.08  0.53 0.51 0.37 0.15 0.14 0.16 
non-tumor DII / 
tumor DII 
         0.86  0.51  1.27  2.67 
Tumor weight (mg)  0 0  0 137  189  310  1,019 
DII was calculated as the ratio of the ctDNA concentrations obtained from the ampliﬁcation of a short/133bp and a long/290bp DNA fragment
from the human ACTB gene, and a short/120bp and a long/338bp DNA fragment from the mouse ACTB gene. Two representative experiments are
shown in upper and lower parts. Results of ampliﬁcations are expressed in terms of concentration (ng/ml of plasma) for each tested mouse with
increasing tumor weight. Data represent values of ctDNA concentration assessed in duplicates. Each mouse was identiﬁed by a diﬀerent number
(Mo n). ND, not detected.
5’ 3’ 5’ 3’
Human beta Actin gene
(chromosome 7) 
Mouse beta Actin gene 
(chromosome 5) 
290 bp 338 bp
  133 bp  120 bp
4353
4510   4643 
4643    2156  2494
2374 2494
Figure 8. Schematic of the primer sets used for evaluating ctDNA fragmentation in plasma of xenografted mice by targeting mouse or human ACTB
sequences. Numbers in italics represent the nucleotide position of the ACTB sequences according to the FASTA format (5566782 for HuACTB and
143665420 for MoACTB).
6170 Nucleic Acids Research, 2010,Vol.38, No. 18Sensitivity and reproducibility of the results obtained with
the diﬀerent primer sets may be further enhanced by sys-
tematic optimization of Q–PCR reactions, but the level
obtained in this study seems satisfactory relative to our
objectives.
Our data indicate that plasma samples give more
speciﬁc results than serum samples for tumor ctDNA
quantiﬁcation at least when originating from xenotrans-
planted CRC cells. Both plasma and serum samples have
been frequently used for ctDNA analysis. Higher ctDNA
levels were previously observed in serum than in plasma
(37) certainly due to DNA release from blood cells follow-
ing clotting. As a consequence plasma levels were increas-
ingly used (4,5,9,22,38). Moreover, serum and plasma
ctDNA levels were found not to be correlated, each
being related in a diﬀerent way to diagnosis and prognosis
(39). Ellinger et al. (32) recently suggested that plasma and
serum ctDNA concentrations might vary depending on
the extraction kit employed. We carried out a rigorous
two-step separation by centrifugation which completely
removed cells from plasma samples intended for DNA
extraction (data not shown). Then, we quantiﬁed wild-
type and mutated ctDNA and evaluated ctDNA fragmen-
tation. We detected tumor-derived ctDNA in all mice
tested using diﬀerent sets of primers. By MASA-PCR
assay using a primer set that targeted mutated KRAS,
Garcia-Olmo and co-workers (40) could detect
tumor-derived ctDNA in only 17–46% of rats xenografted
with DHD CRC cells. Rago et al. (41) described an
elegant and sensitive model to determine tumor ctDNA
level in xenografts by a direct PCR assay targeting the
human Long Interspersed Nuclear Element-1 (LINE-1)
retrotransposon. It has a 3- to 5-fold lower detection
limit than ours and certainly higher robustness at very
low ctDNA concentrations, for instance when quantifying
ctDNA concentration after i.v. injection of tumor cells
(41). Nevertheless, our system also requires small
amounts of plasma (25ml) allowing repeated measure-
ments on the same animal when sampling at least
10days post-injection (data not shown). Moreover, our
animal model exhibits ctDNA levels/tumor weight ratios
comparable to those obtained in the study by Rago and
co-workers when the plasma samples came from xeno-
grafted animals with tumor weight >100mg.
Plasma ctDNA determined by using speciﬁc murine
primer sets did not vary much compared to tumor size
especially up to 1000mg of tumor weight. In contrast,
ctDNA from human origin increased with tumor mass
as it was just detectable in mice bearing low weight
tumors (>100 and <500mg), but could be eight times
more concentrated in plasma from mice bearing high
weight tumors. In mice with tumors of 1–2g, total
ctDNA amount (human- plus mouse-derived ctDNA)
reached 38ng/ml, a concentration that corresponds to
8400copies/ml plasma. There is a variation of ctDNA
mean values in the literature certainly due to the popula-
tions tested or the methods employed. ctDNA amount
was shown in various reports (3,5,6,9,11,42–44) to vary
from 5 to 24ng/ml in healthy individuals. Variations of
ctDNA concentration in cancer patients is primarily due
to the type of neoplasia; for instance, the mean ctDNA
concentration determined in plasma/serum of patients
with small cell lung, prostate and colorectal cancer were
respectively 25, 210 and 1157ng/ml (43,44,11, respective-
ly). In terms of fragment number, Diehl et al. (12)
reported that 1350–230000 fragments/ml were found in
CRC patients’ plasma in comparison to the 1150–8280
fragments/ml in disease-free patients. This illustrates the
overlap between ctDNA level in healthy and CRC indi-
viduals. A highly sensitive approach (ﬂow cytometry
BEAMing analysis of KRAS, PIK3CA, TP53 and APC)
gave a median of 4000 fragments/ml plasma in 18 subjects
with CRC. This value corresponds to the fragment
number we found in xenografted mice bearing tumors
>1000mg, while it does not clearly match the tumor/
body weight ratio. The ctDNA level in mice with tumors
<1000mg appears lower than the concentration found in
human patients. Indeed, the ctDNA amount we found in
mice with tumors of 1–2g (5–10% body weight) was
almost 10-fold lower than that found in advanced CRC
patients. Moreover, the ctDNA level in non-xenografted
nude mice was very low (0.3ng/ml) when compared
with that of healthy human individuals ( 15ng/ml).
Nevertheless, our experimental model highlights the
Table 3. ctDNA fragmentation in plasma samples from healthy subjects and mCRC patients
Human CRC Patients Plasmas                                            Human Healthy Plasmas
HCP001 HCP002 HCP003 HHP001 HHP002 HHP003
ctDNA HuKRASin 145 45 387 846 0.13 1.84 0.42
ng/ml HuKRASin 300 36 300 264 0.37 1.9 0.21
DII 0.8 0.77 0.31 2.75 1.03 1.76
Human CRC Patients Plasmas
HCP001 HCP002 HCP003
ctDNA HuACTB 133 32.1 94.8 308.1
ng/ml HuACTB 290 12.9 68.4 36.9
DII 0.4 0.72 0.12
The DII was calculated as the ratio of the ctDNA concentrations obtained from the ampliﬁcation of a long and a short DNA fragment from both
human KRAS (300/145bp) and ACTB (290/133bp). Results are expressed in terms of concentration (ng/ml of plasma) in the plasma of three healthy
individuals and three mCRC patients. Data represent the ctDNA concentration assessed in triplicate.
Nucleic Acids Research, 2010,Vol.38, No. 18 6171increase of total ctDNA amount with tumor burden as
observed in the clinic (3,11,12,38). Indeed, many authors
proposed to quantify total ctDNA for cancer surveillance
as the overall ctDNA level may depend on the tumor stage
(11,37). Guadalajara et al. (35) found a statistically signiﬁ-
cant correlation between the concentration of ctDNA and
the presence of metastases in CRC patients. Diehl et al.
(13) recently proved that ctDNA measurements could be
used to reliably monitor tumor dynamics in subjects with
CRC who were undergoing surgery or chemotherapy.
Our results suggest that ctDNA could be detected as
early as 16days after cell inoculation (tumor weight
averaging 100mg). Garcia et al. (40) described that the
highest increase in plasma ctDNA concentration was
observed from the end of the ﬁrst week after inoculation
to the end of the ﬁfth week and remained stable thereafter.
Animal model data thus seem to conﬁrm the early
presence of ctDNA after tumor cell inoculation.
It has to be noted that the ctDNA level/tumor weight
ratio seems to be lower in SW620 cell xenografts than in
HT29 cell xenografts. HT29 cells are derived from colo-
rectal adenocarcinoma, whereas SW620 from a metastatic
lymph node of a colorectal adenocarcinoma staged as
Dukes’ type C. Increased number of mice in each group
is needed to strengthen this observation, nevertheless this
illustrates the ability of our system to speciﬁcally investi-
gate and compare ctDNA release in diﬀerent tumor cells,
in particular relative to their original tumor stage.
The total ctDNA amount in CRC patients’ plasma
may originate from the background level observed in
healthy individuals, from cancer cells and from tumor-
surrounding cells or tissues (12). As a consequence the
total ctDNA includes DNA derived from normal and
tumor cells. As tumor cell composition evolves with
tumor progression, it is important to discriminate
among the diﬀerent sources of ctDNA. Only a few
clinical studies tried to determine the mutated/wild-type
ctDNA fragment ratio with very diﬀerent results
(13,39,40). Mutated KRAS was found in 83–86% of
CRC patients’ plasma samples (38). The percentage of
APC mutation varies with the disease stage with only
0.04% in patients with low stage tumor (Dukes’ A),
0.9% in patients without metastases (Dukes’ B) and
11% in advanced cases (Dukes’ D) (11), although no cor-
relation was observed between percentage of mutant
ctDNA and tumor burden (6,13). Jahr et al. (6) detected
in breast cancer patients percentages of tumor-derived
ctDNA going from 3 to 93%. This discrepancy may be
explained by either the neoplasia type or the detection
method employed (CDKN2A hypermethylation).
Furthermore, non-tumor ctDNA level may depend on
many variables, such as phagocyte eﬃciency to remove
dead cells in and around tumors and DNA eﬃciency to
reach the blood circulation. This may explain the large
variation in the amounts and composition of DNA
found in the circulation of cancer patients. Nevertheless,
in CRC patients’ plasma a small proportion of mutated
(tumor) ctDNA was observed. Rago et al. (41) conﬁrmed
that only a tiny fraction of the total plasma ctDNA from
CRC tumor xenografts was of human (tumor) origin.
Conversely, in our study, we found that while
non-tumor ctDNA level did not appear to increase in
mice with tumor weight, the tumor (human origin)/non
tumor (mouse origin) ctDNA ratio signiﬁcantly increased
with the tumor size in both HT29 (1.2 and 13.9) and
SW620 (1.3 and 11, data not shown) xenografted mice
with low and high tumor weight, respectively. We postu-
late that this diﬀerence might be due to the immunodeﬁ-
ciency of nude mice. The ctDNA background level found
in nude mice (0.5ng/ml) is strikingly low compared to that
of immunocompetent mice (10–50ng/ml) or CRC clinical
samples (10–100ng/ml) (data not shown). Therefore we
may assume that T-cells, in particular degenerating,
tumor-inﬁltrating T lymphocytes, may account for a sig-
niﬁcant proportion of ctDNA in clinical samples.
However, Jahr et al. (6) could demonstrate a contribution
from T-cell DNA to the total ctDNA concentration only
in 2 out of 18 patients with diﬀerent cancers (and these
two cases did not include the CRC patients whose plasma
showed 10–1000ng/ml of total ctDNA). Alternatively, the
low levels of non-tumor-derived ctDNA observed in our
model might be explained by other indirect physiological
mechanisms due to the speciﬁc T-cell immunodeﬁciency in
nude mice. Anyway, thanks to the low ctDNA back-
ground, our animal model facilitates the quantiﬁcation
of tumor-derived ctDNA, especially when studying
mutant ctDNA. This is important when examining the
mutated/wild-type fragment ratio and the number of frag-
ments that carry diﬀerent, coexisting mutations. More-
over, the ASB–PCR method we adapted from Morlan
et al. (31) appears as an easy, sensitive and speciﬁc
assay for detecting human SNPs in ctDNA of xenografted
nude mice.
In this study, we further assessed the origin of ctDNA
by analyzing the size of ctDNA fragments within the same
DNA region using primer sets targeting human or mouse
ACTB. Apoptosis is thought to be one of the major
sources of ctDNA in cancer patients as well as in
healthy individuals (10,45) or for fetal ctDNA (46).
Apoptotic events lead to high fragmentation of cell
DNA possibly to fragments of the DNA size contained
in a nucleosome ( 180bp) or multiples of it. ctDNA frag-
ments of nucleosome and oligo-nucleosome size were pre-
viously found in high proportion in CRC patients’ plasma
(15,16,47,48). Our results clearly demonstrate ﬁrst that the
integrity index as determined by this method is much
higher in mouse-derived ctDNA than in human-derived
ctDNA (2.7- to 6.9-fold) and second, they suggest that
the integrity index decreases with tumor size. Thus, our
system conﬁrmed the high predominance of nucleosome-
derived fragments in plasma from xenografted mice and,
as a consequence, of apoptosis as a source of ctDNA.
Moreover, our data indicate that the integrity index of
non-tumor ctDNA does not vary much with tumor size.
The integrity index of non-tumor ctDNA was 1.3–9 times
lower than that of control mice, while it was 7–28 times
lower for tumor ctDNA. Moreover, the integrity index
could discriminate between tumor and non-tumor
ctDNA in all mice tested except for one animal with a
low weight tumor. Ellinger et al. (32) found an integrity
index (384/106bp ratio) of 0.348 and of 0.681 in 74
patients with testicular cancer and 35 healthy individuals,
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ences were observed in patients with benign prostatic
hyperplasia (0.58), urothelial cell carcinoma (0.31) and
prostate cancer (0.11). In addition, they found that
increased ctDNA fragmentation in bladder cancer pa-
tients was correlated with mortality, suggesting that frag-
mentation could be an independent prognostic factor.
Conversely, DNA integrity was not useful in a diagnostic
setting for lung cancer patients (49). If DNA fragmenta-
tion is not a discriminating factor for all cancer types this
means that the mechanisms of DNA release into circula-
tion may change in diﬀerent cancers. In order to better
deﬁne the usefulness of the integrity index, such as the
DII we designed in this study as a clinical diagnostic
factor (complementary to ctDNA quantiﬁcation), it is
thus critical to take into consideration the cancer type.
Only a few reports focused on the use of animal models
for studying ctDNA. Speciﬁcally, Garcia-Olmo’s group
compared directly to tumor ctDNA concentration and
number of circulating cancer cells in xenografted rats
(40). Signiﬁcant ctDNA amounts were detected earlier
and more frequently than circulating tumor cells during
the spread of CRC (40). This suggests a higher potential
for ctDNA as a diagnostic tool than circulating tumor
cells. Rago et al. (41) have developed an elegant and
highly sensitive Q–PCR test to quantify ctDNA by target-
ing LINE-1 in mouse xenografts. They proved that this
system enables in-life monitoring of systemic tumor
burden and therefore the close examination of a variety
of animal tumor models and the eﬃcacy of therapeutic
measures. In this work, we report for the ﬁrst time the
direct evaluation of the respective contribution of the
amount of non-tumor, tumor and mutated ctDNA as
well as the evaluation of ctDNA integrity in an animal
model. Nevertheless, the animal model, we describe here,
can not be fully transposed to human colorectal cancer.
Indeed, human colon cell lines subcutaneously xeno-
grafted in nude mice do not display the same kinetics as
CRC. Moreover, athymic nude mice do not have a func-
tional immune system. Since none of the existing mouse
models mimics all the characteristics of human CRC, each
time the best model should be chosen based on the speciﬁc
experimental questions (49). For instance, an orthotopic
tumor model, like the ones described by Rago et al. (41) or
Samos et al. (50), could possibly be more suitable for
analyzing ctDNA relative to the pathogenesis of metasta-
sis and for the study of tumor–host interactions. However,
orthotopic tumor models might exhibit higher variability
especially concerning tumor homing/inﬁltration in the
host tissue and consequently allow lower reproducibility
when quantifying and diﬀerentiating between non-tumor
and tumor derived ctDNA. On the other hand, here we
detected similar total ctDNA levels in plasma samples
from xenografted animals and from mCRC patients,
while a much higher proportion of tumor ctDNA was
observed in the animal model than in mCRC patients
(12,13). CRC tumor growth seems to lead to higher
ctDNA fragmentation in both mice and patients as sug-
gested by the DII values. The lowest DII value found in
the plasma sample of a healthy subject was higher than the
highest value observed in plasma samples of either CRC
xenografted animals or mCRC patients. These results
suggest that our animal model has some clinical relevance
and that it could be a useful tool for the systematic study
of the form/structure of ctDNA and for screening
methods for ctDNA analysis.
Indeed, our tumor model makes possible the system-
atization of the analysis of ctDNA sources and already
helped us to optimize blood sample manipulation and ex-
traction procedures. Our results suggest that ctDNA mean
size may vary during CRC tumor progression. This might
be due to increased apoptosis. This conclusion is,
however, not universally accepted as conﬂicting conclu-
sions emerge in the literature (6,47,49,51–53). Jahr et al.
(6) could easily detect both large and short ctDNA mol-
ecules upon injection of compounds inducing necrosis and
apoptosis in mice and suggested that large DNA frag-
ments of apparently necrotic origin can best discriminate
cancer patients from healthy individuals. The morpho-
logical assessment of tumors (invasion, diﬀerentiation,
degree of apoptosis) relative to ctDNA fragmentation
would also be informative and could help to resolve this
issue. Moreover, accurate and standardized sampling pro-
cedures, speciﬁc and sensitive detection of ctDNA along
with the use of animal models, like the one used in this
study, might elucidate tumor/non tumor or apoptotic/
necrotic origins of ctDNA relative to variables such
as mutation or tumor location. More has to be done to
better study ctDNA size to establish whether, or to which
extent, a relationship can be drawn between ctDNA size
and tumor stage or tumor types. In addition, our experi-
mental system might be used to diﬀerentiate among the
various forms of ctDNA complexes (speciﬁc or unspeciﬁc
nucleo-proteic, proteo-lipidic, particle-like, etc.) and to
explore the fate of other nucleic acid molecules such as
miRNA, RNA or apoptotic bodies which should provide
precious indications on tumor development. Ultimately
this animal model might be useful for developing
accurate and sensitive diagnostic tests for SNPs detection
which are required for predicting the response to new
potent anti-cancer compounds (25,26) and to determine
whether ctDNA has any function or pathological eﬀects
(37,54,55).
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